Press Releases 

 

First Blood Test to Help Diagnose Brain Injuries gets US Okay

First Blood Test to Help Diagnose Brain Injuries gets US Okay

| February 21, 2018 | 0 comments
by Lindsey Tanner, AP Medical Writer CHICAGO — Feb 14, 2018, 9:04 PM ET The first blood test to help doctors diagnose traumatic brain injuries has won U.S. government approval. The move means Banyan Biomarkers can commercialize its test, giving the company an early lead in the biotech industry’s race to find a way to diagnose
Brain Trauma Indicator, TBI
iPharmaTrials, News, Press Releases
Cannabinoid May Be First Drug for Sleep Apnea

Cannabinoid May Be First Drug for Sleep Apnea

| January 28, 2018 | 0 comments
By Nancy A. Melville / Medscape – Jan 25, 2018 Dronabinol, a synthetic form of the cannabis compound tetrahydrocannabinol (THC), shows efficacy in the treatment of obstructive sleep apnea, possibly representing a first pharmacologic approach to the tough-to-treat, but potentially serious, condition. “These findings support the therapeutic potential of cannabinoids in patients with obstructive sleep
Cannabinoid, Sleep Apnea
iPharmaTrials, News, Press Releases
OVERVIEW OF RESTLESS LEGS SYNDROME

OVERVIEW OF RESTLESS LEGS SYNDROME

| November 3, 2017 | 0 comments
Characterized by an uncomfortable and irresistible urge to move the legs, restless legs syndrome is a sensorimotor disorder involving the nervous system. Restless legs syndrome, also called commonly referred to as RLS or Willis-Ekbom disease, typically worsens when lying or sitting. As a result, the syndrome is commonly accompanied with sleep problems, exhaustion, daytime sleepiness,
Cannabis, cannabis inhalation, cannabis treatments, Restless legs syndrome, RLS, Willis-Ekbom disease
iPharmaTrials, News, Press Releases
Medical Marijuana (Cannabis) & MS

Medical Marijuana (Cannabis) & MS

| September 25, 2017 | 0 comments
The question of whether marijuana — produced from the flowering top of the hemp plant, cannabis sativa — should be used for symptom management in multiple sclerosis (MS) is a complex one. It is generally agreed that better therapies are needed for distressing symptoms of MS — including pain, tremor and spasticity — that may
cannabis on cognition, cannabis sativa, cognitive function, hemp plant, ms, multiple sclerosis, oral cannabis extract
iPharmaTrials, News, Press Releases
Neurological Aspects of Medical Use of Cannabidiol

Neurological Aspects of Medical Use of Cannabidiol

| September 19, 2017 | 0 comments
BACKGROUND: Cannabidiol (CBD) is among the major secondary metabolites of Cannabis devoid of the delta-9-tetra-hydrocannabinol psychoactive effects. It is a resorcinol-based compound with a broad spectrum of potential therapeutic properties, including neuroprotective effects in numerous pathological conditions. CBD neuroprotection is due to its antioxidant and antiinflammatory activities and the modulation of a large number of
Cannabidiol, neurodegenerative diseases, neurological, Neurology, neuroprotection
iPharmaTrials, Press Releases
PAINWeek Abstract Book 2018

PAINWeek Abstract Book 2018

| September 4, 2017 | 0 comments
Excerpt : “Misuse/abuse of prescription opioids has been recognized as a public health crisis by the U.S. Food and Drug Administration (FDA) and the FDA’s Opioid Action Plan recognizes abuse-deterrent (AD) formulations of opioids as critical to mitigating opioid misuse/abuse. Morphine abuse-deterrent, extended-release injection-molded tablets (ADER-IMT) developed to resist common and rigorous forms of physical
abstract book, painweek
News, Press Releases
Cannabidiol Menstrual Cycle

Cannabidiol Menstrual Cycle

| July 18, 2017 | 0 comments
After research it’s been found, CB1 receptor clusters are present in the hypothalamic pituitary access and have been shown to act as an inhibitory. This in turn altering production of hormones, which in turn can affect a women’s hormone cycles. This is something that we believe to not be of risk, but important for the
cannabinoid receptors, CB1, hypothalamic, pituitary gland
News, Press Releases
Brain Chemicals May Aid Treatment of Parkinson’s

Brain Chemicals May Aid Treatment of Parkinson’s

| June 24, 2017 | 0 comments
Stanford Report, by Mitzi Baker Marijuana-like chemicals in the brain may point to a treatment for the debilitating condition of Parkinson’s disease. In a study published in the Feb. 8 issue of Nature, researchers from the School of Medicine report that endocannabinoids, naturally occurring chemicals found in the brain that are similar to the active
dopamine, endocannabinoids, National Parkinson Foundation, Parkinson's Disease
iPharmaTrials, News, Press Releases
Medical Marijuana And Epilepsy

Medical Marijuana And Epilepsy

| April 23, 2017 | 0 comments
Taking cannabidiol may cut seizures in half for some children and adults with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy, according to new information released today from a large scale controlled clinical study that will be presented at the American Academy of Neurology’s 69th Annual Meeting in Boston, April 22 to 28, 2017. Cannabidiol
Cannabis-based medicine, epilepsy, Lennox-Gastaut syndrome, LGS, medical marijuana, seizures
iPharmaTrials, News, Press Releases
Criminal Intent May Be Measurable on Imaging

Criminal Intent May Be Measurable on Imaging

| April 16, 2017 | 0 comments
April 12, 2017 by Deborah Brauser New research suggests the possibility of measuring whether an individual was just reckless while committing a crime or was acting knowingly, which can have more severe legal implications. In the study, 40 participants were told they would need to go through a security checkpoint with a suitcase that may
criminal intent, neuroimaging
iPharmaTrials, IPT Documents, News, Press Releases

Resources

 

– Krishna’s Corner
– Krishna’s Blog
– Store

iPT Tweets

 

News

 

iPHARMA TRIALS

 

New York, USA
Telephone : 718-332-7878
rkrishna -AT- ipharmatrials.com
.. replace -AT- with @

United Kingdom
The Studio/East Batterlaw Farm
Seaham SR7 8RP

Corporation Registration Address:
330 Thornton Road Englewood NJ 07631